Clinical trials: Steroid Resistant Acute Graft Versus Host Disease
Graft Vs Host Disease
Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD)
The primary goal of this study is to determine the safety and tolerability of a novel peptide - preimplantation factor (PIF-1) - in patients who develop acute steroid-resistant graft-versus-host disease (GVHD) after matched bone…
- Trial name
- PIF1GVHD (NCT00517907)
- Testing
- Preimplantation factor (PIF-1)
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- Hadassah Medical Organization
COPD, Emphysema or COPD
Steroid Resistance During COPD Exacerbations With Respiratory Failure
Chronic obstructive pulmonary disease (COPD) is a lung disease caused by cigarette smoke that affects millions of people. In the United States, COPD is the 3rd leading cause of death making it one of our most important public…
- Conditions
- COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute
- Trial name
- NCT03680495
- Testing
- Methylprednisolone
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Colorado, Denver
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Acute Graft-versus-host Disease
MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
The purpose of this study is to compare the efficacy of CD25 monoclonal antibody and calcineurin inhibitors with or without mesenchymal stem cells (MSCs) in treating patients with steroid-resistant acute graft-versus-host disease…
- Trial name
- NCT02241018
- Testing
- CD25 monoclonal antibody, calcineurin inhibitors, MSCs
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Graft vs Host Disease
Ruxolitinib In GvHD
The preliminary data demonstrate potent activity of Ruxolitinib in steroid-refractory aGvHD. In this phase 2 trial the efficacy of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute GvHD in…
- Trial name
- RIG (NCT02396628)
- Testing
- Experimental intervention, Standard treatment
- Where
- 11 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Prof. Dr. Nikolas von Bubnoff
Stem Cell Transplant Complications, Graft Versus Host Disease, Acute
Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease
The investigators hypothesize that perturbations in the intestinal microbiota following allogeneic hematopoietic stem cell transplantation (HSCT) are essential for the development and propagation of acute graft-versus-host…
- Conditions
- Stem Cell Transplant Complications, Graft Versus Host Disease, Acute, Fecal Microbiota Transplantation
- Trial name
- NCT03214289
- Testing
- Fecal Microbiota Transplantation
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Sheba Medical Center
Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease
FMT for Steroid Resistant Gut Acute GVHD
The study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of steroid resistant graft-versus-host-disease (GVHD) of the gut.
- Conditions
- Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease, Fecal Microbiota Transplantation
- Trial name
- NCT04285424
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Acute Graft Versus Host Disease
Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)
Post allogeneic hematopoietic stem cell transplantation (HSCT) patients with steroid resistant acute GVHD localised to the liver will receive 24 hours continuous intra-arterial infusion of methylprednisolone.
- Trial name
- NCT01140984
- Testing
- Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Hadassah Medical Organization
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA
Graft-versus-host Disease
Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease
The aims of the study: 1. To evaluate the clinical efficacy of the use of extracorporeal photopheresis in the treatment of Graft-versus-host disease under standard clinical indications as pre-defined by the participants Centers…
- Trial name
- BIOECP_GVHD (NCT03124056)
- Testing
- Extracorporeal photopheresis
- Volunteers
- 62 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Safety and Efficacy
Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD
Acute graft-versus-host disease (aGVHD) is the most common life-threatening complication of allogeneic hematopoietic stem cell transplantation. The recognized first-line treatment for grade 3-4 aGVHD is systemic glucocorticoid.
- Trial name
- NCT05021276
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Steroid Resistant Acute Graft Versus Host Disease
Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease
Leukotac (inolimomab) is not approved yet for marketing in any region. In the absence of medical options and based on the safety and efficacy data obtained during the clinical development program (in a phase III (INO-107) and in…
- Trial name
- NCT05047328
- Testing
- inolimomab
- Where
- France
- Sponsor
- ElsaLys Biotech
Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease
Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease
This phase I trial studies the side effects of using an investigational procedure (fecal microbiota transplantation [FMT]) in treating patients with severe acute gut graft-versus-host-disease.
- Conditions
- Acute Graft Versus Host Disease, Gastrointestinal Tract Acute Graft Versus Host Disease, Severe Gastrointestinal Tract Acute Graft Versus Host Disease, Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
- Trial name
- NCT04280471
- Testing
- Fecal Microbiota Transplantation Capsule
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Graft vs Host Disease
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
Steroids are still the first line treatment for established severe acute-graft-versus-host-disease (aGVHD), with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory (aGVHD).
- Trial name
- NCT02770430
- Testing
- mesenchymal stem cells, conventional treatment
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Acute Graft Versus Host Disease
Anti-CD3 & Anti-CD7 Ricin A Immunotoxin-Combination for Acute Graft Versus Host Disease
In this study, a combination of two T-cell directed antibodies both conjugated to a cell-killing toxin will be evaluated. Previous in vitro studies have demonstrated that this so-called immunotoxin-combination (IT-combination)…
- Trial name
- NCT00640497
- Testing
- IT-Combination
- Where
- 3 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Henogen
Hematopoietic and Lymphoid Cell Neoplasm
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD
The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD).
- Trial name
- FEMITGIGVHD (NCT03812705)
- Testing
- fecal microbiome transplantation
- Where
- 2 sites in China
- Volunteers
- 6 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Cancer, Graft-Versus-Host Disease
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
A clinical trial to assess safety and two regimens of (MEDI-507) a drug given to stem cell and bone marrow recipients who have a mid-grade acute Graft-versus-Host Disease.
- Trial name
- NCT00806728
- Testing
- MEDI-507
- Where
- 10 sites in United States
- Volunteers
- 17 people
- Sponsor
- MedImmune LLC
Graft Vs Host Disease
A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease
This is an academic open-label, phase II randomized study in patients with steroid resistant severe acute Graft versus host disease (GvHD) who have had allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05132166
- Testing
- Drug or biologic - anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib., Decidual Stromal Cells
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Graft vs Host Disease
Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD
In this study, a combination of two antibodies both conjugated to a cell-killing toxin (so-called immunotoxins) will be evaluated.
- Trial name
- NCT02027805
- Testing
- T-Guard
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Xenikos
Graft-versus-host Disease, Poor Graft Function
Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function
The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD.
- Conditions
- Graft-versus-host Disease, Poor Graft Function, Low Donor T-cell Chimerism
- Trial name
- NCT00603330
- Testing
- Mesenchymal stem cells
- Where
- 12 sites in Belgium, Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Liege